Cormorant Asset Management, LP Centessa Pharmaceuticals PLC Transaction History
Cormorant Asset Management, LP
- $628 Million
- Q3 2025
A detailed history of Cormorant Asset Management, LP transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,925,000 shares of CNTA stock, worth $53.1 Million. This represents 7.43% of its overall portfolio holdings.
Number of Shares
1,925,000
Previous 2,086,600
7.74%
Holding current value
$53.1 Million
Previous $27.4 Million
70.26%
% of portfolio
7.43%
Previous 2.76%
Shares
11 transactions
Others Institutions Holding CNTA
# of Institutions
139Shares Held
125MCall Options Held
1.49MPut Options Held
787K-
Medicxi Ventures Management (Jersey) LTD20MShares$551 Million73.31% of portfolio
-
Avoro Capital Advisors LLC New York, NY10.8MShares$298 Million3.58% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA10MShares$277 Million0.41% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$275 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$267 Million8.3% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $2.6B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...